OCUL vs. RVMD, GRFS, TGTX, NUVL, LNTH, RYTM, AXSM, TLX, CRSP, and PCVX
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.
Ocular Therapeutix vs. Its Competitors
Revolution Medicines (NASDAQ:RVMD) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.
In the previous week, Revolution Medicines had 3 more articles in the media than Ocular Therapeutix. MarketBeat recorded 6 mentions for Revolution Medicines and 3 mentions for Ocular Therapeutix. Revolution Medicines' average media sentiment score of 0.99 beat Ocular Therapeutix's score of 0.63 indicating that Revolution Medicines is being referred to more favorably in the media.
Ocular Therapeutix has higher revenue and earnings than Revolution Medicines. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -323.09%. Revolution Medicines' return on equity of -37.06% beat Ocular Therapeutix's return on equity.
94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Revolution Medicines has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.
Revolution Medicines currently has a consensus target price of $68.91, suggesting a potential upside of 81.82%. Ocular Therapeutix has a consensus target price of $17.33, suggesting a potential upside of 41.96%. Given Revolution Medicines' higher possible upside, equities research analysts clearly believe Revolution Medicines is more favorable than Ocular Therapeutix.
Summary
Revolution Medicines beats Ocular Therapeutix on 11 of the 15 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
This page (NASDAQ:OCUL) was last updated on 7/25/2025 by MarketBeat.com Staff
Free OCUL Stock Alerts